Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953963911> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2953963911 endingPage "S390" @default.
- W2953963911 startingPage "S390" @default.
- W2953963911 abstract "Chronic disease management requires sequential drug treatments, as toxicities develop and responses wane. Non-medical switching (NMS) is described as a change in drug therapy for non-clinical reasons, such as payer formulary, economic, or patient preference. This study aimed to assess community rheumatologists’ experience with and perceptions of NMS between originator biologics and their biosimilars in routine clinical practice. We surveyed US-based rheumatologists from various geographic locations and practice types in October and November 2018 to understand NMS of originator to biosimilars for rheumatoid arthritis (RA). Physician characteristics and responses were summarized using descriptive statistics. Among 54 participating rheumatologists, 45% practiced in suburban areas and 7% rural; 24% were solo practitioners, and 38% were from a small, medium, or large private community practice. Mean years in practice were 19 years (range 3-40). Biosimilars were used among 33 (61%) participating rheumatologists to treat patients with RA. Over one-third of rheumatologists reported increased use of biosimilars. Most common concerns for prescribing biosimilars were efficacy (43%), safety (41%), and patient’s insurance policy constraint (31%). Of 25 rheumatologists who switched at least one RA patient from Remicade (originator) to Inflectra (biosimilar) in the past year, 56% reported that NMS comprised >75% of these switches. Approximately one-third (35%) reported that prescribing biosimilars provided cost-savings to their practice and/or patients, one-third reported that they were not cost-saving, and the remaining 31% were not aware of the cost. The use of biosimilars for RA patients is increasing among US rheumatologists. The majority of the switching appears to be for non-medical reasons, and a minority of rheumatologists report cost-savings related to biosimilars. Further research is needed to assess the cost-effectiveness and comparative effectiveness of biosimilars versus originator biologics in RA." @default.
- W2953963911 created "2019-07-12" @default.
- W2953963911 creator A5047311973 @default.
- W2953963911 creator A5050300851 @default.
- W2953963911 creator A5050866878 @default.
- W2953963911 creator A5078528446 @default.
- W2953963911 creator A5086111354 @default.
- W2953963911 date "2019-05-01" @default.
- W2953963911 modified "2023-09-27" @default.
- W2953963911 title "TP2 COMMUNITY RHEUMATOLOGISTS' EXPERIENCE AND VIEWS ON NON-MEDICAL SWITCHING TO BIOSIMILARS" @default.
- W2953963911 doi "https://doi.org/10.1016/j.jval.2019.04.1906" @default.
- W2953963911 hasPublicationYear "2019" @default.
- W2953963911 type Work @default.
- W2953963911 sameAs 2953963911 @default.
- W2953963911 citedByCount "0" @default.
- W2953963911 crossrefType "journal-article" @default.
- W2953963911 hasAuthorship W2953963911A5047311973 @default.
- W2953963911 hasAuthorship W2953963911A5050300851 @default.
- W2953963911 hasAuthorship W2953963911A5050866878 @default.
- W2953963911 hasAuthorship W2953963911A5078528446 @default.
- W2953963911 hasAuthorship W2953963911A5086111354 @default.
- W2953963911 hasBestOaLocation W29539639111 @default.
- W2953963911 hasConcept C100406419 @default.
- W2953963911 hasConcept C126322002 @default.
- W2953963911 hasConcept C142724271 @default.
- W2953963911 hasConcept C177713679 @default.
- W2953963911 hasConcept C204787440 @default.
- W2953963911 hasConcept C2426938 @default.
- W2953963911 hasConcept C2777575956 @default.
- W2953963911 hasConcept C2779974597 @default.
- W2953963911 hasConcept C512399662 @default.
- W2953963911 hasConcept C59491497 @default.
- W2953963911 hasConcept C71924100 @default.
- W2953963911 hasConcept C98274493 @default.
- W2953963911 hasConceptScore W2953963911C100406419 @default.
- W2953963911 hasConceptScore W2953963911C126322002 @default.
- W2953963911 hasConceptScore W2953963911C142724271 @default.
- W2953963911 hasConceptScore W2953963911C177713679 @default.
- W2953963911 hasConceptScore W2953963911C204787440 @default.
- W2953963911 hasConceptScore W2953963911C2426938 @default.
- W2953963911 hasConceptScore W2953963911C2777575956 @default.
- W2953963911 hasConceptScore W2953963911C2779974597 @default.
- W2953963911 hasConceptScore W2953963911C512399662 @default.
- W2953963911 hasConceptScore W2953963911C59491497 @default.
- W2953963911 hasConceptScore W2953963911C71924100 @default.
- W2953963911 hasConceptScore W2953963911C98274493 @default.
- W2953963911 hasLocation W29539639111 @default.
- W2953963911 hasOpenAccess W2953963911 @default.
- W2953963911 hasPrimaryLocation W29539639111 @default.
- W2953963911 hasRelatedWork W1987232315 @default.
- W2953963911 hasRelatedWork W2003372003 @default.
- W2953963911 hasRelatedWork W2107614826 @default.
- W2953963911 hasRelatedWork W2108228943 @default.
- W2953963911 hasRelatedWork W2303039077 @default.
- W2953963911 hasRelatedWork W2322591539 @default.
- W2953963911 hasRelatedWork W2347052005 @default.
- W2953963911 hasRelatedWork W2523563455 @default.
- W2953963911 hasRelatedWork W2901238754 @default.
- W2953963911 hasRelatedWork W4224231189 @default.
- W2953963911 hasVolume "22" @default.
- W2953963911 isParatext "false" @default.
- W2953963911 isRetracted "false" @default.
- W2953963911 magId "2953963911" @default.
- W2953963911 workType "article" @default.